XML 38 R28.htm IDEA: XBRL DOCUMENT v3.22.4
DEBT (Tables)
3 Months Ended
Dec. 31, 2022
DEBT  
Schedule of long-term debt

Long term debt as of December 31, 2022 and September 30, 2022 is detailed in the table below.

    

December 31, 2022

    

September 30, 2022

Seller Note – Bolder BioPath

 

752

 

808

Seller Note – Preclinical Research Services

590

615

Seller Note – Plato BioPharma

643

1,470

Seller Payable - Orient BioResource Center

3,553

3,488

Seller Note – Histion

325

369

Seller Note – Protypia

600

600

Economic Injury Disaster Loan

140

140

Convertible Senior Notes

106,346

104,965

Term Loan Facility, DDTL and Incremental Term Loans

272,513

238,200

 

385,462

 

350,655

Less: Current portion

 

(7,553)

 

(7,979)

Less: Debt issuance costs not amortized

 

(12,266)

 

(11,999)

Total long-term debt

$

365,643

$

330,677

As of December 31, 2022, the Company did not have an outstanding balance on the revolving credit facility.